Mitani Kazutaka, Tsuboi Ichiro, Tanaka Gen, Yosioka Saori, Yokoyama Shuhei, Kobayashi Yusuke, Nakajima Hirochika, Nagami Taichi, Ogawa Kohei, Wada Koichiro
Department of Urology Shimane University Faculty of Medicine Izumo Shimane Japan.
IJU Case Rep. 2023 Dec 19;7(2):127-130. doi: 10.1002/iju5.12684. eCollection 2024 Mar.
Small cell bladder cancer is a relatively rare tumor, representing <1% of all bladder tumors. Amrubicin monotherapy is used as second-line treatment for small cell lung cancer in Japan.
A 79-year-old woman presented with gross hematuria and was diagnosed with small cell bladder cancer (T2 or higher). Neoadjuvant chemotherapy with etoposide and cisplatin resulted in a partial response. Robot-assisted radical cystectomy was performed, and radical resection was achieved. As we identified metastasis in the pleura 1 year later, we administered carboplatin and etoposide, which resulted in a partial response. Although pembrolizumab was initiated as maintenance therapy, it was not effective. Amrubicin was given as third-line therapy, and stable disease was achieved without serious adverse effect for 6 months.
Although there is no established treatment for metastatic small cell bladder cancer, the current case report suggests the effectiveness of amrubicin in this setting.
小细胞膀胱癌是一种相对罕见的肿瘤，占所有膀胱肿瘤的比例不到1%。在日本，氨柔比星单药疗法被用作小细胞肺癌的二线治疗。
一名79岁女性因肉眼血尿就诊，被诊断为小细胞膀胱癌（T2期或更高分期）。依托泊苷和顺铂新辅助化疗取得部分缓解。实施了机器人辅助根治性膀胱切除术，并实现了根治性切除。1年后，我们发现胸膜转移，遂给予卡铂和依托泊苷治疗，取得部分缓解。尽管开始使用帕博利珠单抗作为维持治疗，但无效。给予氨柔比星作为三线治疗，病情稳定达6个月，且无严重不良反应。
尽管转移性小细胞膀胱癌尚无既定的治疗方法，但本病例报告提示氨柔比星在这种情况下具有有效性。
